Evaluation of the effect of choline-stabilized orthosilicic acid (ch-OSA®) in patients with tennis elbow
| ISRCTN | ISRCTN12631735 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN12631735 |
| ClinicalTrials.gov (NCT) | Nil known |
| Clinical Trials Information System (CTIS) | Nil known |
| Protocol serial number | 17/3 |
| Sponsor | Bio Minerals NV |
| Funder | Bio Minerals NV |
- Submission date
- 04/09/2020
- Registration date
- 15/09/2020
- Last edited
- 25/08/2022
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Musculoskeletal Diseases
Plain English summary of protocol
Background and study aims
Lateral epicondylitis, also known as "Tennis Elbow", is the most common overuse syndrome in the elbow. Most of the traditional treatments such as anti-inflammatory medications, rest, physical therapy and corticosteroid injections do not alter the tendon's poor healing properties.
Choline-stabilized orthosilicic acid has been reported to improve the symptoms of soft tissue injuries (i.e. pain relief and improved mobility).
This study will investigate whether choline-stabilized orthosilicic acid can relieve the symptoms of epicondylitis.
Who can participate?
Adults between the ages of 18 and 70 with epicondylitis symptoms lasting 12 weeks or longer
What does the study involve?
Patients are randomly allocated to either receive choline-stabilized orthosilicic acid or placebo (dummy capsule). All patients will be instructed to take two capsules daily for 20 weeks. Assessments will be done at the screening visit, inclusion to the study, and after 5, 10, 15 and 20 weeks of treatment. If necessary, rescue medication in the form of paracetamol (up to 4 g/day) is permitted up to 48 hours before the baseline visit and other study visits.
What are the possible benefits and risks of participating?
Choline-stabilized orthosilicic acid may support soft tissue healing. Considering the available information about choline-stabilized orthosilicic acid, there are no foreseeable risks to human health when used as instructed.
Where is the study run from?
Bio Minerals NV (Belgium)
When is the study starting and how long is it expected to run for?
March 2017 to January 2023
Who is funding the study?
Bio Minerals NV (Belgium)
Who is the main contact?
Prof. Dr Alexander Van Tongel
alexander.vantongel@ugent.be
Contact information
Public
Zenderstraat 12
Destelbergen
9070
Belgium
 ORCID ID |
0000-0001-8177-1138 |
|---|---|
| Phone | +32 (0)9 3351327 |
| mattias.bonnarens@biominerals.be |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Multi-center double-blind randomized placebo-controlled phase III study |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | A randomized, double-blind placebo-controlled study to assess the effect of choline-stabilized orthosilicic acid on lateral epicondylitis |
| Study objectives | The aim of the study is to evaluate the effect of oral intake of choline-stabilized orthosilicic acid over a 20 week period on the symptoms of lateral epicondylitis. |
| Ethics approval(s) | Approved 05/03/2018, Central ethical committee: Commission for Medical Ethics/Commissie voor Medische Ethiek (UZ Gent, entrance 75, route 7522, Corneel Heymanslaan 10, 9000 Gent, Belgium; +32 (0)9 332 49 62; ethisch.comite@uzgent.be), ref: not provided |
| Health condition(s) or problem(s) studied | Lateral epicondylitis |
| Intervention | Participants are randomized to either the placebo or active treatment group (choline-stabilized orthosilicic acid) using block randomization in a ratio of 1:1. All participants will be instructed to take daily for 20 weeks, two capsules orally of either placebo (520 mg microcrystalline cellulose beadlets), or the active ingredient (520 mg beadlets containing 5 mg of silicon and 100 mg of choline in the form of choline-stabilized orthosilicic acid). The trial starts with a screening visit and a wash-out period during which the use of lateral epiconylititis treatment is not permitted. Assessments will be done respectively at inclusion (baseline), and after 5, 10, 15 and 20 weeks of treatment. If necessary, rescue medication under the form of paracetamol (up to 4g/day) is permitted up to 48 hours before the baseline visit and other study visits. |
| Intervention type | Supplement |
| Primary outcome measure(s) |
Elbow pain severity measured using a visual analog scale (VAS, 100mm) at baseline and 20 weeks |
| Key secondary outcome measure(s) |
1. Disabilities of the Arm, Shoulder and Hand (DASH) score measured using DASH questionnaire at baseline, 5, 10, 15 and 20 weeks |
| Completion date | 31/01/2023 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 130 |
| Total final enrolment | 148 |
| Key inclusion criteria | 1. Provision of written informed consent 2. Males, pre-menopausal females, peri- or post-menopausal females currently taking hormone replacement therapy between the ages of 18 and 70 years old 3. Females must use an approved form of birth control 4. Painful, chronic tendinopathy present in lateral elbow in one arm. The baseline elbow is > 40 on a scale of 100 mm (VAS: "0" representing no pain and "100" worst imaginable pain) during elbow extension and resisted wrist extension (Cozen's test) 5. The epicondylitis symptoms lasting at least 12 weeks or longer 6. A history of at least two periods of elbow pain lasting >10 days 7. BMI between 18.5 and 35 kg/m² 8. Participant must continue his/her normal physical activities during the study i.e. there should be no change in physical activity after the screening visit |
| Key exclusion criteria | 1. Unable to understand the study procedures and/or not wishing to participate in one of the subsequent therapeutic intervention protocols 2. Poor general health interfering with compliance or assessment 3. Unlikely to co-operate fully in the study 4.. Participating in another clinical trial in the last 90 days 5. Pregnancy or breastfeeding 6. Radiological examinations show abnormalities such as arthritis and inflammatory arthropathy of the elbow joint in the target arm 7. Participants with a history of trauma, ligament damage, fracture, tumor or surgery of the elbow joint in the target arm 8. Proven and current symptomatic peripheral nerve entrapment syndrome 9. Proven and current symptomatic cervical facet arthrosis: C5-C6/C6-C7 10. Proven and current symptomatic radiculopathy 11. Fibromyalgia, chronic fatigue syndrome 12. New physical activity i.e. physical activity which was not present prior to the screening visit 13. Recent or current alcohol abuse 14. Participants with documented, active infection diseases such as HIV or hepatitis B/C 15. Clinically significant medical abnormalities which would make the subject unsuitable for the study, as judged by the investigator, such as mental disorders 16. Participant has documented renal failure, history of stroke, myocardial infarct or cancer 17. Concomitant and previous medication 17.1. Less than 6 months between the local treatment of epicondylitis with platelet-rich plasma (PRP), autologous conditioned plasma (ACP) or autologous whole blood (AWB) injections and inclusions in the study 17.2. Less than 3 months between the local treatment of epicondylitis with shockwaves or steroid injections and inclusion in the study 17.3. Less than 6 weeks between the local treatment of epicondylitis with botulinum toxin, glycosaminoglycan polysulfate (hyaluronic acid) or dextrose injections and inclusion in the study 17.4. Less than 15 days between the treatment and inclusion in the study: systemic or topical use of NSAIDs and analgesics, different from paracetamol; systemic opoids and corticosteroids; treatment for epicondylitis with acupuncture or physiotherapy 17.5. Less than 3 months between supplementation with food supplements containing horsetail extract, bamboo extract, silicic acid or silanol derivatives and inclusion in the study |
| Date of first enrolment | 24/05/2018 |
| Date of final enrolment | 31/08/2022 |
Locations
Countries of recruitment
- Belgium
Study participating centres
Corneel Heymanslaan 10
Ghent
9000
Belgium
Corneel Heymanslaan 10
Ghent
9000
Belgium
Stevenslei 20
Deurne
2100
Belgium
Genk
3600
Belgium
Groenebriel 1
Ghent
9000
Belgium
Sint-Lucaslaan 29
Brugge
8310
Belgium
Sint-Lucaslaan 29
Brugge
8310
Belgium
Ruddershove 10
Brugge
8000
Belgium
Wilrijkstraat 10
Edegem-Antwerp
2650
Belgium
Turnhout
2300
Belgium
Wilrijk
2610
Belgium
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| IPD sharing plan | The data-sharing plans for the current study are unknown and will be made available at a later date. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
25/08/2022: The following changes were made to the trial record:
1. The contact was updated.
2. The total final enrolment was added.
08/03/2022: The following changes were made to the trial record:
1. The recruitment end date was changed from 30/03/2022 to 31/08/2022.
2. The overall trial end date was changed from 31/08/2022 to 31/01/2023 and the plain English summary has been updated to reflect this change.
06/09/2021: The following changes were made to the trial record:
1. The recruitment end date was changed from 30/09/2021 to 30/03/2022.
2. The overall trial end date was changed from 31/01/2022 to 31/08/2022.
3. The intention to publish date was changed from 30/06/2022 to 31/12/2023.
11/01/2021: The following changes were made to the trial record:
1. The recruitment end date was changed from 31/01/2021 to 30/09/2021.
2. The overall trial end date was changed from 30/06/2021 to 31/01/2022.
3. The intention to publish date was changed from 31/12/2021 to 30/06/2022.
14/09/2020: Trial's existence confirmed by Commission for Medical Ethics, UZ Gent.
